In vitro effects of acetylcholinesterase reactivators on monoamine oxidase activity

Toxicology Letters

Volumn 201, Issue 2, 2011, Pages 176-180

  Fišar, Zdeněk ^a   Hroudová, Jana ^a   Korábečný, Jan ^b   Musílek, Kamil ^c   Kuča, Kamil ^d,e  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

^d UNIVERSITY OF DEFENCE   (Czech Republic)

^e UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

HI 6; Methoxime; Monoamine oxidase; Obidoxime; Oxime; Pralidoxime; Trimedoxime

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CHOLINESTERASE REACTIVATOR; METHOXIME; MONOAMINE; OBIDOXIME; OXIDOREDUCTASE; PRALIDOXIME; TRIMEDOXIME; UNCLASSIFIED DRUG;

ARTICLE; BRAIN; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MITOCHONDRION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; BRAIN; CHOLINESTERASE REACTIVATORS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; OBIDOXIME CHLORIDE; OXIMES; PRALIDOXIME COMPOUNDS; PYRIDINIUM COMPOUNDS; SWINE; TRIMEDOXIME;

SUIDAE;

EID: 79651474816     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.12.023     Document Type: Article

References (45)

1. Bach A.W.J., Lan N.C., Johnson D.L., Abell C.W., Bembenek M.E., Kwan S.W., Seeburg P.H., Shih J.C. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. U.S.A. 1988, 85(13):4934-4938.
2. Bajgar J., Fusek J., Kuca K., Bartosova L., Jun D. Treatment of organophosphate intoxication using cholinesterase reactivators: facts and fiction. Mini Rev. Med. Chem. 2007, 7(5):461-466.
3. Cheng Y.-C., Prusoff W.H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22(23):3099-3108.
4. Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol. Rev. 2003, 22(3):165-190.
5. Eyer P., Worek F., Thiermann H., Eddleston M. Paradox findings may challenge orthodox reasoning in acute organophosphate poisoning. Chem. Biol. Interact. 2010, 187(1-3):270-278.
6. Fišar Z. Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch. Pharmacol. 2010, 381(6):563-572.
7. Fišar Z., Hroudová J., Raboch J. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. NeuroEndocrinol. Lett. 2010, 31(5):645-656.
8. Fowler C.J., Tipton K.F. Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochem. Pharmacol. 1981, 30(24):3329-3332.
9. Garcia G.E., Campbell A.J., Olson J., Moorad-Doctor D., Morthole V.I. Novel oximes as blood-brain barrier penetrating cholinesterase reactivators. Chem. Biol. Interact. 2010, 187(1-3):199-206.
10. Hiraoka A., Ohtaka J., Koike S., Tsuboi Y., Tsuchikawa S., Miura I. Inhibition of copper-containing amine oxidase by oximes. Chem. Pharm. Bull. (Tokyo) 1988, 36(8):3027-3031.
11. Horstink M., Tolosa E., Bonuccelli U., Deuschl G., Friedman A., Kanovsky P., Larsen J.P., Lees A., Oertel W., Poewe W., Rascol O., Sampaio C. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur. J. Neurol. 2006, 13(11):1170-1185.
12. Karasova J.Z., Kassa J., Musilek K., Pohanka M., Novotny L., Kuca K. Effect of seven newly synthesized and currently available oxime cholinesterase reactivators on cyclosarin-intoxicated rats. Int. J. Mol. Sci. 2009, 10(7):3065-3075.
13. Kassa J., Karasova J.Z., Bajgar J., Tesarova S., Kuca K., Musilek K. Evaluation of the neuroprotective efficacy of newly developed oximes (K206, K269) and currently available oximes (obidoxime, HI-6) in cyclosarin-poisoned rats. Basic Clin. Pharmacol. Toxicol. 2009, 104(3):228-235.
14. Kassa J., Karasova J.Z., Musilek K., Kuca K., Jung Y.-S. A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats. Toxicol. Mech. Methods 2009, 19(3):232-238.
15. Kassa J., Kuca K., Karasova J., Musilek K. The development of new oximes and the evaluation of their reactivating, therapeutic and neuroprotective efficacy against tabun. Mini Rev. Med. Chem. 2008, 8(11):1134-1143.
16. Kuca K., Jun D., Bajgar J. Currently used cholinesterase reactivators against nerve agent intoxication: comparison of their effectivity in vitro. Drug Chem. Toxicol. 2007, 30(1):31-40.
17. Kuca K., Marek J., Karasova J., Pohanka M., Korabecny J., Kalasz H. Novel acetylcholinesterase reactivator-oxime K048-reactivation activity in vitro. Med. Chem. 2010, 6(1):1-5.
18. Kuca K., Musilek K., Jun D., Pohanka M., Ghosh K.K., Hrabinova M. Oxime K027: novel low-toxic candidate for the universal reactivator of nerve agent- and pesticide-inhibited acetylcholinesterase. J. Enzyme Inhib. Med. Chem. 2010, 25(4):509-512.
19. Kunešová G., Kassa J. Comparison of effects of different antidotes on tabun-induced cognitive impairment in rats using water maze. Acta Medica (Hradec Králové) 2006, 49(2):113-118.
20. Lorke D.E., Kalasz H., Petroianu G.A., Tekes K. Entry of oximes into the brain: a review. Curr. Med. Chem. 2008, 15(8):743-753.
21. Lorke D.E., Petroianu G.A. Minireview: does in-vitro testing of oximes help predict their in-vivo action after paraoxon exposure?. J. Appl. Toxicol. 2009, 29(6):459-469.
22. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193(1):265-275.
23. Mlíčková K., Šebela M., Cibulka R., Frébort I., Peč P., Liška F., Tanizawa K. Inhibition of copper amine oxidases by pyridine-derived aldoximes and ketoximes. Biochimie 2001, 83(11-12):995-1002.
24. Ögren S.O., Eriksson T.M., Elvander-Tottie E., D'Addario C., Ekström J.C., Svenningsson P., Meister B., Kehr J., Stiedl O. The role of 5-HT1A receptors in learning and memory. Behav. Brain Res. 2008, 195(1):54-77.
25. Peter J.V., Moran J.L., Graham P. Oxime therapy and outcomes in human organophosphate poisoning: an evaluation using meta-analytic techniques. Crit. Care Med. 2006, 34(2):502-510.
26. Rahimi R., Nikfar S., Abdollahi M. Increased morbidity and mortality in acute human organophosphate-poisoned patients treated by oximes: a meta-analysis of clinical trials. Hum. Exp. Toxicol. 2006, 25(3):157-162.
27. Ramsay R.R., Gravestock M.B. Monoamine oxidases: to inhibit or not to inhibit. Mini Rev. Med. Chem. 2003, 3(2):129-136.
28. Sakurada K., Ikegaya H., Ohta H., Fukushima H., Akutsu T., Watanabe K. Effects of oximes on mitochondrial oxidase activity. Toxicol. Lett. 2009, 189(2):110-114.
29. Shih T.M., Skovira J.W., O'Donnell J.C., McDonough J.H. Evaluation of nine oximes on in vivo reactivation of blood, brain, and tissue cholinesterase activity inhibited by organophosphorus nerve agents at lethal dose. Toxicol. Mech. Methods 2009, 19(6-7):386-400.
30. Shrot S., Markel G., Dushnitsky T., Krivoy A. The possible use of oximes as antidotal therapy in organophosphate-induced brain damage. Neurotoxicology 2009, 30(2):167-173.
31. Soukup O., Kristofikova Z., Proska J., Tobin G., Patocka J., Marek J., Jun D., Fusek J., Ripova D., Kuca K. Novel acetylcholinesterase reactivator K112 and its cholinergic properties. Biomed. Pharmacother. 2010, 64(8):541-545.
32. Soukup O., Tobin G., Kumar U.K., Binder J., Proska J., Jun D., Fusek J., Kuca K. Interaction of nerve agent antidotes with cholinergic systems. Curr. Med. Chem. 2010, 17(16):1708-1718.
33. Stahl S.M., Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008, 13(10):855-870.
34. Suzuki O., Seno H., Kumazawa T. In vitro inhibition of human platelet monoamine oxidase by phenothiazine derivatives. Life Sci. 1988, 42(21):2131-2136.
35. Tattersall J.E. Ion channel blockade by oximes and recovery of diaphragm muscle from soman poisoning in vitro. Br. J. Pharmacol. 1993, 108(4):1006-1015.
36. Thiermann H., Eyer F., Felgenhauer N., Pfab R., Zilker T., Eyer P., Worek F. Pharmacokinetics of obidoxime in patients poisoned with organophosphorus compounds. Toxicol. Lett. 2010, 197(3):236-242.
37. van Helden H.P., Busker R.W., Melchers B.P., Bruijnzeel P.L. Pharmacological effects of oximes: how relevant are they?. Arch. Toxicol. 1996, 70(12):779-786.
38. van Helden H.P., de Lange J., Busker R.W., Melchers B.P. Therapy of organophosphate poisoning in the rat by direct effects of oximes unrelated to ChE reactivation. Arch. Toxicol. 1991, 65(7):586-593.
39. Voicu V.A., Bajgar J., Medvedovici A., Radulescu F.S., Miron D.S. Pharmacokinetics and pharmacodynamics of some oximes and associated therapeutic consequences: a critical review. J. Appl. Toxicol. 2010, 30(8):719-729.
40. Voicu V.A., Thiermann H., Rǎdulescu F.S., Mircioiu C., Miron D.S. The toxicokinetics and toxicodynamics of organophosphonates versus the pharmacokinetics and pharmacodynamics of oxime antidotes: biological consequences. Basic Clin. Pharmacol. Toxicol. 2010, 106(2):73-85.
41. Whittaker V.P. Handbook of Neurochemistry, Vol. II Structural Neurochemistry 1969, 327-364. The synaptosome., Plenum Press, New York, London. A. Lajtha (Ed.).
42. Willems J.L., De Bisschop H.C., Verstraete A.G., Declerck C., Christiaens Y., Vanscheeuwyck P., Buylaert W.A., Vogelaers D., Colardyn F. Cholinesterase reactivation in organophosphorus poisoned patients depends on the plasma concentrations of the oxime pralidoxime methylsulphate and of the organophosphate. Arch. Toxicol. 1993, 67(2):79-84.
43. Worek F., Aurbek N., Wille T., Eyer P., Thiermann H. Kinetic analysis of interactions of paraoxon and oximes with human, Rhesus monkey, swine, rabbit, rat and guinea pig acetylcholinesterase. Toxicol. Lett. 2011, 200(1-2):19-23.
44. Youdim M.B., Bakhle Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br. J. Pharmacol. 2006, 147(Suppl 1):S287-S296.
45. Youdim M.B., Edmondson D., Tipton K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 2006, 7(4):295-309.